BACKGROUND: Vitamin D deficiency has been associated with adverse health outcomes. PURPOSE: To systematically review benefits and harms of vitamin D screening in asymptomatic adults. DATA SOURCES: Ovid MEDLINE (through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. STUDY SELECTION: Randomized trials of screening for and treatment of vitamin D deficiency and case-control studies nested within the Women's Health Initiative. DATA EXTRACTION: One investigator abstracted data, a second reviewed data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. DATA SYNTHESIS: No study examined the effects of vitamin D screening versus no screening on clinical outcomes. Vitamin D treatment was associated with decreased mortality versus placebo or no treatment (11 studies; risk ratio [RR], 0.83 [95% CI, 0.70 to 0.99]), although benefits were no longer seen after trials of institutionalized persons were excluded (8 studies; RR, 0.93 [CI, 0.73 to 1.18]). Vitamin D treatment was associated with possible decreased risk for having at least 1 fall (5 studies; RR, 0.84 [CI, 0.69 to 1.02]) and falls per person (5 studies; incidence rate ratio, 0.66 [CI, 0.50 to 0.88]) but not fractures (5 studies; RR, 0.98 [CI, 0.82 to 1.16]). Vitamin D treatment was not associated with a statistically significant increased risk for serious adverse events (RR, 1.17 [CI, 0.74 to 1.84]). LIMITATION: Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment doses, use of calcium, and duration of follow-up. CONCLUSION: Treatment of vitamin D deficiency in asymptomatic persons might reduce mortality risk in institutionalized elderly persons and risk for falls but not fractures. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
BACKGROUND:Vitamin D deficiency has been associated with adverse health outcomes. PURPOSE: To systematically review benefits and harms of vitamin D screening in asymptomatic adults. DATA SOURCES: Ovid MEDLINE (through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. STUDY SELECTION: Randomized trials of screening for and treatment of vitamin D deficiency and case-control studies nested within the Women's Health Initiative. DATA EXTRACTION: One investigator abstracted data, a second reviewed data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. DATA SYNTHESIS: No study examined the effects of vitamin D screening versus no screening on clinical outcomes. Vitamin D treatment was associated with decreased mortality versus placebo or no treatment (11 studies; risk ratio [RR], 0.83 [95% CI, 0.70 to 0.99]), although benefits were no longer seen after trials of institutionalized persons were excluded (8 studies; RR, 0.93 [CI, 0.73 to 1.18]). Vitamin D treatment was associated with possible decreased risk for having at least 1 fall (5 studies; RR, 0.84 [CI, 0.69 to 1.02]) and falls per person (5 studies; incidence rate ratio, 0.66 [CI, 0.50 to 0.88]) but not fractures (5 studies; RR, 0.98 [CI, 0.82 to 1.16]). Vitamin D treatment was not associated with a statistically significant increased risk for serious adverse events (RR, 1.17 [CI, 0.74 to 1.84]). LIMITATION: Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment doses, use of calcium, and duration of follow-up. CONCLUSION: Treatment of vitamin D deficiency in asymptomatic persons might reduce mortality risk in institutionalized elderly persons and risk for falls but not fractures. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Authors: Sâmia Araújo de Sousa Studart; Ana Caroline Rocha Melo Leite; Aryana Lushese Lima Feitosa Marinho; Ana Carolina Matias Dinelly Pinto; Carlos Nobre Rabelo Júnior; Rodolfo de Melo Nunes; Hermano Alexandre Lima Rocha; Francisco Airton Castro Rocha Journal: Rheumatol Int Date: 2015-05-20 Impact factor: 2.631
Authors: Erin D Michos; Christine M Mitchell; Edgar R Miller; Alice L Sternberg; Stephen P Juraschek; Jennifer A Schrack; Sarah L Szanton; Jeremy D Walston; Rita R Kalyani; Timothy B Plante; Robert H Christenson; Dave Shade; James Tonascia; David L Roth; Lawrence J Appel Journal: Contemp Clin Trials Date: 2018-08-20 Impact factor: 2.226
Authors: Stefan Pilz; Nicolas Verheyen; Martin R Grübler; Andreas Tomaschitz; Winfried März Journal: Nat Rev Cardiol Date: 2016-05-06 Impact factor: 32.419
Authors: P Peris; X Filella; A Monegal; N Guañabens; L Foj; M Bonet; D Boquet; E Casado; D Cerdá; A Erra; C Gómez-Vaquero; S Martínez; N Montalá; C Pittarch; E Kanterewicz; M Sala; X Suris; J L Carrasco Journal: Osteoporos Int Date: 2017-05-02 Impact factor: 4.507